David Bonita
Independent DirectorDr. David P. Bonita, M.D., M.B.A, is Director of Alpfa Medical, Inc. He is Independent Director of Windward Bio AG and Windward Bio Group AG from January 2025. Dr. Bonita serves as Director of Magenta Medical LTD. He is a Director of Congruence Therapeutics Inc. He serves as a General Partner at OrbiMed Advisors LLC since February 2020. He serves as an Independent Director at ImageneBio, Inc. since July 2025. He is a Co-Founder and serves as Chairman, President and Director at Rampart Bioscience, Inc. He served as a Private Equity Partner at OrbiMed Advisors, LLC from June 2013 to February 2020. He served as Private Equity Principal from December 2007 to June 2013 and Senior Associate from June 2004 to December 2007 at the firm. From June 2004 to June 2013, he held various positions at OrbiMed Advisors LLC. He joined OrbiMed Advisors LLC in June 2004. As of February 2020, he is a member of OrbiMed Advisors LLC. he has been an Independent Director of Acutus Medical, Inc. since June 2013. He serves as the Director of Sublimity Therapeutics Ltd., previously known as Sigmoid Pharma Ltd. since May 2018. He worked as a Corporate Finance Analyst in the healthcare investment banking groups of Morgan Stanley & Co. from February 1998 to July 1999 and a Corporate Finance Analyst in the healthcare investment banking group of UBS AG from August 1997 to February 1998. He had been the Chairman of Clementia Pharmaceuticals, Inc. since June 2013 and had been its Independent Director since April 2013 until April 2019.He also previously served on the boards of directors of IMARA Inc. and SI-BONE, Inc. He served as an Interim Chairman of the Board of Tricida, Inc. and had been its Non-Employee Director since January 2014 until January 23, 2023. He served as a Director of ViewRay, Inc. from January 2008 to June 25, 2018. He serves as a Director at Keystone Heart, Ltd., Alexion Montréal Corp. and CardiAQ Valve Technologies, Inc. He has been Independent Director of Imara, Inc., since March 2019. He has been an Independent Director of Repare Therapeutics Inc. since September 2019. He was Director of SI-Bone Inc. since April 2014 until June 13, 2019. He served as an Independent Director of Ikena Oncology, Inc. since March 2016. He serves as an Independent Director of Prelude Therapeutics Inc. since June 2016. He also serves as an Observer on the boards of Roka Bioscience, SuperDimension and Insulet. He also serves on the Boards of Directors of several private companies. He served as an Independent Director of Loxo Oncology, Inc. from October 2013 to December 22, 2017. He served as a Director of Ambit Biosciences Corporation from October 2012 to November 10, 2014. He has extensive investment experience in the healthcare industry. He serves as an Independent Director of Third Harmonic Bio, Inc. since July 2020. He has published scientific articles in peer reviewed journals based on signal transduction research performed at the Harvard Medical School.He received a B.A., magna cum laude, in Biological Sciences and Biology from Harvard University in 1993 to 1997 and a M.D. from Columbia University College of Physicians and Surgeons, where he was elected to the Alpha Omega Alpha Medical Honor Society in 1999 to 2004 and a M.B.A. from Columbia University - Columbia Business School, where he was elected to the Beta Gamma Sigma Business Honor Society 2003 to 2004. serves as a General Partner at OrbiMed Advisors LLC since February 2020. He is a Co-Founder and serves as Chairman, President and Director at Rampart Bioscience, Inc. He served as a Private Equity Partner at OrbiMed Advisors, LLC from June 2013 to February 2020. He served as Private Equity Principal from December 2007 to June 2013 and Senior Associate from June 2004 to December 2007 at the firm. From June 2004 to June 2013, He held various positions at OrbiMed Advisors LLC. He joined OrbiMed Advisors LLC in June 2004. As of February 2020, He is a member of OrbiMed Advisors LLC. Dr. Bonita has been an Independent Director of Acutus Medical, Inc. since June 2013. He serves as the Director of Sublimity Therapeutics Ltd., previously known as Sigmoid Pharma Ltd. since May 2018. He worked as a Corporate Finance Analyst in the healthcare investment banking groups of Morgan Stanley & Co. from February 1998 to July 1999 and a Corporate Finance Analyst in the healthcare investment banking group of UBS AG from August 1997 to February 1998. He had been the Chairman of Clementia Pharmaceuticals, Inc. since June 2013 and had been its Independent Director since April 2013 until April 2019. Dr. Bonita also previously served on the boards of directors of IMARA Inc. and SI-BONE, Inc. He served as an Interim Chairman of the Board of Tricida, Inc. and had been its Non-Employee Director since January 2014 until January 23, 2023. He served as a Director of ViewRay, Inc. from January 2008 to June 25, 2018. He serves as a Director at Keystone Heart, Ltd., Alexion Montréal Corp. and CardiAQ Valve Technologies, Inc. He has been Independent Director of Imara, Inc., since March 2019. He has been an Independent Director of Repare Therapeutics Inc. since September 2019. He was Director of SI-Bone Inc. since April 2014 until June 13, 2019. He served as an Independent Director of Ikena Oncology, Inc. since March 2016. He serves as an Independent Director of Prelude Therapeutics Inc. since June 2016. He also serves as an Observer on the boards of Roka Bioscience, SuperDimension and Insulet. He also serves on the Boards of Directors of several private companies. He served as an Independent Director of Loxo Oncology, Inc. from October 2013 to December 22, 2017. He served as a Director of Ambit Biosciences Corporation from October 2012 to November 10, 2014. He has extensive investment experience in the healthcare industry. He serves as an Independent Director of Third Harmonic Bio, Inc. since July 2020. He has published scientific articles in peer reviewed journals based on signal transduction research performed at the Harvard Medical School. Dr. Bonita received a B.A., magna cum laude, in Biological Sciences and Biology from Harvard University in 1993 to 1997 and a M.D. from Columbia University College of Physicians and Surgeons, where he was elected to the Alpha Omega Alpha Medical Honor Society in 1999 to 2004 and a M.B.A. from Columbia University - Columbia Business School, where he was elected to the Beta Gamma Sigma Business Honor Society 2003 to 2004.
Positions
- Company NameAcutus Medical, Inc.Stock CodeAFIBPositionIndependent Director
- Company NamePrelude Therapeutics IncorporatedStock CodePRLDPositionIndependent DirectorColleagues
- KVKrishna VaddiFounder, CEO & Director
- PAPaul A. FriedmanIndependent Chairman of the Board
- BDBryant David LimCFO, Chief Legal Officer & Corporate Secretary
- PAPeggy A. ScherleChief Scientific Officer
- ACAimee CrombieSenior VP and Head of Strategic Planning & Operations
- MPMadhu PudipeddiSenior Vice President of Technical Operations
- DBDavid BonitaIndependent Director
- VSVictor SandorIndependent Director
- KDKatina DortonIndependent Directors
- Company NameImageneBio, Inc.Stock CodeIMAPositionLead Independent DirectorColleagues
- KYKristin YaremaCEO & Director
- JJJonathan Jian WangChairman
- YGYanina Grant-HuertaCFO, Principal Financial Officer & Principal Accounting Officer
- KPKurinji PandiyanChief Strategy & Operations Officer
- RSRenuka SivendranChief Technical Officer
- MRMatt RobbinsGeneral Counsel
- DBDavid BonitaLead Independent Director
- OSOtello StampacchiaIndependent Director
- JPJoseph P. SlatteryDirector
- Company NameWindward Bio Group AGStock CodeWWBPositionIndependent DirectorColleagues
- LSLuca SantarelliCEO & Chair of the Board of Directors
- CDClaudia D'AugustaChief Financial Officer
- KAKevin Andrew HarrisChief Operating Officer
- NKNoel KurdiSenior Vice President of Investor Relations & Communications
- SAScott ApplebaumChief Legal & Corporate Development Officer
- SSSandip S. KapadiaLead Independent Director
- OSOtello StampacchiaIndependent Director
- IRIqbal Rasool MuftiIndependent Director
